HT
ABCL icon

Headlands Technologies’s AbCellera Biologics ABCL Stock Holding History

Headlands Technologies’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.93M Buy
246,252
+63,596
+35% +$311K 0.21% 121
2026
Q1 		$637K Sell
182,656
-6,131
-3% -$22.1K 0.07% 305
2025
Q4 		$646K Buy
188,787
+69,196
+58% +$309K 0.05% 356
2025
Q3 		$602K Buy
119,591
+81,796
+216% +$360K 0.05% 321
2025
Q2 		$130K Buy
+37,795
New +$94.1K 0.02% 573
2024
Q3 		– Sell
-49,393
Closed -$146K – 1145
2024
Q2 		$146K Buy
+49,393
New +$187K 0.02% 543

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Headlands Technologies's ABCL Position: Q2 2026 in Review

Headlands Technologies increased its AbCellera Biologics (ABCL) stake by 35% in Q2 2026, buying an estimated $311K and bringing the position to 246,252 shares worth $1.93M. The position accounts for 0.21% of the portfolio, ranked #121.

Headlands Technologies first reported a position in ABCL in Q2 2024 and has held it in 6 quarters since. 150 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • Headlands Technologies held 246,252 shares of AbCellera Biologics worth $1.93M as of Q2 2026.
  • Headlands Technologies bought 63,596 AbCellera Biologics shares in Q2 2026, an estimated $311K.
  • AbCellera Biologics made up 0.21% of Headlands Technologies's portfolio in Q2 2026, its #121 holding.
  • Headlands Technologies first reported a position in AbCellera Biologics in Q2 2024 and has held it in 6 quarters since.
  • 150 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Headlands Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.